Glen Pearson

Professor of Medicine (Cardiology)

University of Alberta

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Glen Pearson is a Professor of Medicine (Cardiology) at the University of Alberta, Canada. His research focuses on cardiovascular disease prevention and management, with recent articles addressing lipoprotein(a) testing, guidelines for dyslipidemia, and the role of pharmacists in acute coronary syndrome care. He has significantly contributed to the understanding of atherosclerotic cardiovascular disease risk and is involved in updating national clinical guidelines in this field.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (1)

Hazal Babadagli

Clinical Assistant Professor

The University of British Columbia

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Glen Pearson

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study.

Prevention and Management of Cardiovascular Disease in Primary Care: A Comment on the PEER Simplified Lipid Guideline.

Assessment of immunosuppression induction with basiliximab compared to antithymocyte‐globulin in adult heart transplant patients

Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults

Increased Lp(a) Workload Volumes Reflect Uptake of the 2021 Canadian Cardiovascular Society Guidelines for Management of Dyslipidemia

Pharmacist-Led Follow-Up Program for Rural Patients with Acute Coronary Syndrome: The PLURAL-ACS Pilot Program

Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists

Explaining the TG cut-off in the 2021 lipid guidelines for when clinicians should rely on non-HDL-C or ApoB

Ligne directrice C-CHANGE pour l’harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022

Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists

Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

Lipid therapy: A new whiteboard video for patient education

Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery

Collaborators (1)

Hazal Babadagli

Make your next move.